tirzepatide wada FDA Grants a New Indication for Obesity Management TrimRX | Tirzepatide: Dual Action
Description
This is a phase 3, multicenter, randomized, placebo-controlled, double- blinded clinical trial investigating the efficacy and safety of maximum tolerated dose (MTD) of tirzepatide (10 mg or 15 mg) administered once weekly (QW) subcutaneously compared with placebo for body weight management, in participants who have obesity, or overweight with at least 1 obesity-related complication (excluding type 2 diabetes), and with at least 5% weight reduction following a 12-week intensive lifestyle intervention lead-in
BY INDICATION The diabetes indication segment accounted for the largest share of the market
If 50 units still produces steady results, there is no reason to increase
Clinical trials show 1018% weight loss over 612 months at this dose level, translating to 2040 pounds for most patients
Simon Birk Jensen and colleagues involved a randomized clinical trial with 195 participants
The Food and Drug Administration (FDA) has approved Tirzepatide, commercially known as Mounjaro , for the treatment of type 2 diabetes
